Impact of body mass index (BMI) on the efficacy and safety of halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion in patients with plaque psoriasis

被引：0
|
作者：
Lebwohl, Mark G. [1 ]
Del Rosso, James Q. [2 ]
Alonso-Llamazares, Javier [3 ]
Lattouf, Mark [4 ]
Jacobson, Abby [4 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Thomas Dermatol, JDR Dermatol Res, Las Vegas, NV USA
[3] Miami Vet Affairs Healthcare Syst, Miami, FL USA
[4] Ortho Dermatol, Bridgewater, NJ USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27124
引用
收藏
页码：AB130 / AB130
页数：1
相关论文
共 50 条
  • [31] Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies
    Sugarman, Jeffrey L.
    Weiss, Jonathan
    Tanghetti, Emil A.
    Bagel, Jerry
    Yamauchi, Paul S.
    Gold, Linda Stein
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    Israel, Robert
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 855 - 861
  • [32] Efficacy, safety and tolerability of a halobetasol 0.01%/tazarotene 0.045% fixed combination in the treatment of moderate-to-severe plaque psoriasis in a Hispanic population: Post hoc analysis of 2 phase III randomized controlled trials
    Alexis, Andrew F.
    Bagel, Jerry
    Cook-Bolden, Fran E.
    Lin, Tina
    Kang, Robert
    Mathew, Lindsey
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB202 - AB202
  • [33] Comparison of biologic initiation and health care costs among patients with psoriasis receiving fixed-dose combination halo-betasol-propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion vs calcipotriene 0.005%/betamethasone dipropionate 0.064% (CAL/BD) foam
    Kircik, Leon
    Joseph, George
    Gagnon-Sanschagrin, Patrick
    Bumpass, Brock
    Serra, Elizabeth
    Jacobson, Abby
    Guerin, Annie
    Glick, Brad P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB57 - AB57
  • [34] Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis
    Wu, Jashin J.
    Hansen, Jes B.
    Patel, Dharm S.
    Nyholm, Nanna
    Veverka, Karen A.
    Swensen, Andrine R.
    JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (06) : 641 - 649
  • [35] The effect of biologic treatment on body-mass index (BMI) in chronic plaque psoriasis patients
    Yee, J.
    Varigos, G. A.
    Radulski, B.
    Braue, A.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2013, 54 : 60 - 60
  • [36] Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
    Adam, David N.
    Bernasconi, Marie Y. Jablonski
    Thoning, Henrik
    Wu, Jashin J.
    DERMATOLOGY AND THERAPY, 2022, 12 (11) : 2589 - 2600
  • [37] Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
    David N. Adam
    Marie Y. Jablonski Bernasconi
    Henrik Thoning
    Jashin J. Wu
    Dermatology and Therapy, 2022, 12 : 2589 - 2600
  • [38] Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
    Giles, Jon T.
    Ogdie, Alexis
    Gomez Reino, Juan J.
    Helliwell, Philip
    Germino, Rebecca
    Stockert, Lori
    Young, Pamela
    Joseph, Wael
    Mundayat, Rajiv
    Graham, Daniela
    Ritchlin, Christopher
    RMD OPEN, 2021, 7 (01):
  • [39] IMPACT OF BASELINE BODY MASS INDEX ON THE EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS
    Ritchlin, C. T.
    Ogdie, A.
    Giles, J. T.
    Gomez-Reino, J. J.
    Helliwell, P.
    Stockert, L.
    Young, P.
    Joseph, W.
    Mundayat, R.
    Graham, D.
    Woolcott, J.
    Romero, A. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1713 - 1714
  • [40] Impact of Baseline Body Mass Index on the Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis
    Ritchlin, Christopher
    Ogdie, Alexis
    Giles, Jon
    Gomez-Reino, Juan
    Helliwell, Philip
    Stockert, Lori
    Young, Pamela
    Joseph, Wael
    Mundayat, Rajiv
    Graham, Daniela
    Woolcott, John
    Romero, Ana
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
12345